182 related articles for article (PubMed ID: 27155464)
41. Design, synthesis and antiproliferative activity of novel 5-nitropyrimidine-2,4-diamine derivatives bearing alkyl acetate moiety.
Zhao PL; Li YH; Yang HK; Chen P; Zhang B; Sun Q; Li Q; You WW
Eur J Med Chem; 2016 Aug; 118():161-9. PubMed ID: 27128180
[TBL] [Abstract][Full Text] [Related]
42. Synthesis and evaluation of 2,7-diamino-thiazolo[4,5-d] pyrimidine analogues as anti-tumor epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors.
Lin R; Johnson SG; Connolly PJ; Wetter SK; Binnun E; Hughes TV; Murray WV; Pandey NB; Moreno-Mazza SJ; Adams M; Fuentes-Pesquera AR; Middleton SA
Bioorg Med Chem Lett; 2009 Apr; 19(8):2333-7. PubMed ID: 19286381
[TBL] [Abstract][Full Text] [Related]
43. Novel 5-substituted, 2,4-diaminofuro[2,3-d]pyrimidines as multireceptor tyrosine kinase and dihydrofolate reductase inhibitors with antiangiogenic and antitumor activity.
Gangjee A; Zeng Y; Ihnat M; Warnke LA; Green DW; Kisliuk RL; Lin FT
Bioorg Med Chem; 2005 Sep; 13(18):5475-91. PubMed ID: 16039863
[TBL] [Abstract][Full Text] [Related]
44. Synthesis of novel thiazolyl-pyrimidines and their anticancer activity in vitro.
Shi HB; Li HB; Lu KQ; Zhu XR; Hu WX; Pei W
Arch Pharm (Weinheim); 2011 Oct; 344(10):675-83. PubMed ID: 21984017
[TBL] [Abstract][Full Text] [Related]
45. Characterization of compound 584, an Abl kinase inhibitor with lasting effects.
Puttini M; Redaelli S; Moretti L; Brussolo S; Gunby RH; Mologni L; Marchesi E; Cleris L; Donella-Deana A; Drueckes P; Sala E; Lucchini V; Kubbutat M; Formelli F; Zambon A; Scapozza L; Gambacorti-Passerini C
Haematologica; 2008 May; 93(5):653-61. PubMed ID: 18367480
[TBL] [Abstract][Full Text] [Related]
46. Design and synthesis of novel pyrazolo[1,5-a]pyrimidine derivatives bearing nitrogen mustard moiety and evaluation of their antitumor activity in vitro and in vivo.
Zhao M; Ren H; Chang J; Zhang D; Yang Y; He Y; Qi C; Zhang H
Eur J Med Chem; 2016 Aug; 119():183-96. PubMed ID: 27162123
[TBL] [Abstract][Full Text] [Related]
47. Facile synthesis and antiproliferative activity of 7H-benzo[7,8]chromeno[2,3-d]pyrimidin-8-amines.
Akrami H; Safavi M; Mirjalili BF; Dehghani Ashkezari M; Dadfar F; Mohaghegh N; Emami S; Salehi F; Nadri H; Ardestani SK; Firoozpour L; Khoobi M; Foroumadi A
Eur J Med Chem; 2017 Feb; 127():128-136. PubMed ID: 28039771
[TBL] [Abstract][Full Text] [Related]
48. Synthesis, anticancer activity and effects on cell cycle profile and apoptosis of novel thieno[2,3-d]pyrimidine and thieno[3,2-e] triazolo[4,3-c]pyrimidine derivatives.
Kandeel MM; Refaat HM; Kassab AE; Shahin IG; Abdelghany TM
Eur J Med Chem; 2015 Jan; 90():620-32. PubMed ID: 25499930
[TBL] [Abstract][Full Text] [Related]
49. Design, synthesis and biological evaluation of novel condensed pyrrolo[1,2-c]pyrimidines featuring morpholine moiety as PI3Kα inhibitors.
Ibrahim MA; Abou-Seri SM; Hanna MM; Abdalla MM; El Sayed NA
Eur J Med Chem; 2015 Jun; 99():1-13. PubMed ID: 26037808
[TBL] [Abstract][Full Text] [Related]
50. Synthesis and biological evaluation of novel 1-substituted 3-(3-phenoxyprop-1-yn-1-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-amines as potent Bruton's tyrosine kinase (BTK) inhibitors.
Zheng N; Hao Q; Lin K; Pan J; Li Y; Zhou W
Bioorg Med Chem Lett; 2019 Jan; 29(2):225-229. PubMed ID: 30522954
[TBL] [Abstract][Full Text] [Related]
51. Synthesis and antitumor activities of some new N1-(flavon-6-yl)amidrazone derivatives.
Habashneh AY; El-Abadelah MM; Zihlif MA; Imraish A; Taha MO
Arch Pharm (Weinheim); 2014 Jun; 347(6):415-22. PubMed ID: 24615985
[TBL] [Abstract][Full Text] [Related]
52. Design, synthesis, anticancer activity and docking studies of novel 4-morpholino-7,8-dihydro-5H-thiopyrano[4,3-d]pyrimidine derivatives as mTOR inhibitors.
Zhu W; Sun C; Xu S; Wu C; Wu J; Xu M; Zhao H; Chen L; Zeng W; Zheng P
Bioorg Med Chem; 2014 Dec; 22(24):6746-54. PubMed ID: 25468038
[TBL] [Abstract][Full Text] [Related]
53. Design, synthesis, and in vitro antitumor evaluation of novel phenylaminopyrimidine derivatives.
Zheng Y; Zheng M; Liu Y; Xue Y; Zhang L; An L; Liu L; Ji M
Med Chem; 2013 May; 9(3):340-50. PubMed ID: 22920155
[TBL] [Abstract][Full Text] [Related]
54. Design, synthesis and biological evaluation of novel 6-alkenylamides substituted of 4-anilinothieno[2,3-d]pyrimidines as irreversible epidermal growth factor receptor inhibitors.
Ji X; Peng T; Zhang X; Li J; Yang W; Tong L; Qu R; Jiang H; Ding J; Xie H; Liu H
Bioorg Med Chem; 2014 Apr; 22(7):2366-78. PubMed ID: 24565969
[TBL] [Abstract][Full Text] [Related]
55. Discovery of 5-(2-(phenylamino)pyrimidin-4-yl)thiazol-2(3H)-one derivatives as potent Mnk2 inhibitors: synthesis, SAR analysis and biological evaluation.
Diab S; Teo T; Kumarasiri M; Li P; Yu M; Lam F; Basnet SK; Sykes MJ; Albrecht H; Milne R; Wang S
ChemMedChem; 2014 May; 9(5):962-72. PubMed ID: 24677692
[TBL] [Abstract][Full Text] [Related]
56. Synthesis of novel trifluoromethyl substituted furo[2,3-b]pyridine and pyrido[3',2':4,5]furo[3,2-d]pyrimidine derivatives as potential anticancer agents.
Naresh Kumar R; Poornachandra Y; Nagender P; Mallareddy G; Ravi Kumar N; Ranjithreddy P; Ganesh Kumar C; Narsaiah B
Eur J Med Chem; 2016 Jan; 108():68-78. PubMed ID: 26629861
[TBL] [Abstract][Full Text] [Related]
57. Synthesis, biological evaluation and molecular docking studies of some pyrimidine derivatives.
Fargualy AM; Habib NS; Ismail KA; Hassan AM; Sarg MT
Eur J Med Chem; 2013 Aug; 66():276-95. PubMed ID: 23811090
[TBL] [Abstract][Full Text] [Related]
58. Synthesis and biological evaluation of novel dasatinib analogues as potent DDR1 and DDR2 kinase inhibitors.
Liu L; Hussain M; Luo J; Duan A; Chen C; Tu Z; Zhang J
Chem Biol Drug Des; 2017 Mar; 89(3):420-427. PubMed ID: 27589335
[TBL] [Abstract][Full Text] [Related]
59. Synthesis of novel benzo[4,5]thiazolo[1,2-a]pyrimidine-3-carboxylate derivatives and biological evaluation as potential anticancer agents.
Nagarapu L; Vanaparthi S; Bantu R; Ganesh Kumar C
Eur J Med Chem; 2013 Nov; 69():817-22. PubMed ID: 24113366
[TBL] [Abstract][Full Text] [Related]
60. Design and synthesis of novel 3-sulfonylpyrazol-4-amino pyrimidines as potent anaplastic lymphoma kinase (ALK) inhibitors.
Zhang P; Dong J; Zhong B; Zhang D; Yuan H; Jin C; Xu X; Li H; Zhou Y; Liang Z; Ji M; Xu T; Song G; Zhang L; Chen G; Meng X; Sun D; Shih J; Zhang R; Hou G; Wang C; Jin Y; Yang Q
Bioorg Med Chem Lett; 2016 Apr; 26(8):1910-8. PubMed ID: 26979157
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
